Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer

Stromal content heavily impacts the transcriptional classification of colorectal cancer (CRC), with clinical and biological implications. Lineage-dependent stromal transcriptional components could therefore dominate over more subtle expression traits inherent to cancer cells. Since in patient-derived xenografts (PDXs) stromal cells of the human tumour are substituted by murine counterparts, here we deploy human-specific expression profiling of CRC PDXs to assess cancer-cell intrinsic transcriptional features. Through this approach, we identify five CRC intrinsic subtypes (CRIS) endowed with distinctive molecular, functional and phenotypic peculiarities: (i) CRIS-A: mucinous, glycolytic, enriched for microsatellite instability or KRAS mutations; (ii) CRIS-B: TGF-β pathway activity, epithelial–mesenchymal transition, poor prognosis; (iii) CRIS-C: elevated EGFR signalling, sensitivity to EGFR inhibitors; (iv) CRIS-D: WNT activation, IGF2 gene overexpression and amplification; and (v) CRIS-E: Paneth cell-like phenotype, TP53 mutations. CRIS subtypes successfully categorize independent sets of primary and metastatic CRCs, with limited overlap on existing transcriptional classes and unprecedented predictive and prognostic performances.

[1]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[2]  Camille Stephan-Otto Attolini,et al.  Stromal gene expression defines poor-prognosis subtypes in colorectal cancer , 2015, Nature Genetics.

[3]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[4]  G. Gores,et al.  Hepatic stellate cells: Partners in crime for liver metastases? , 2011, Hepatology.

[5]  Andreas Schlicker,et al.  Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition , 2013, International journal of cancer.

[6]  Sabine Tejpar,et al.  Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer , 2013, The Journal of pathology.

[7]  Sabine Tejpar,et al.  IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies , 2015, Science Translational Medicine.

[8]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[9]  Daniel Q. Naiman,et al.  Simple decision rules for classifying human cancers from gene expression profiles , 2005, Bioinform..

[10]  G. Inghirami,et al.  Stromal contribution to the colorectal cancer transcriptome , 2015, Nature Genetics.

[11]  R. Scharpf,et al.  The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer , 2015, Nature.

[12]  T. Ørntoft,et al.  Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer , 2009, Clinical Cancer Research.

[13]  Pablo Tamayo,et al.  Metagenes and molecular pattern discovery using matrix factorization , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Gallinger,et al.  Microsatellite Instability as a Prognostic Factor in Resected Colorectal Cancer Liver Metastases , 2004, Annals of Surgical Oncology.

[15]  Julian Gehring,et al.  SomaticSignatures: inferring mutational signatures from single-nucleotide variants , 2014, bioRxiv.

[16]  Hans Clevers,et al.  The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. , 2011, Cell stem cell.

[17]  Marco Beccuti,et al.  The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets , 2015, Nature Communications.

[18]  Therese Sørlie,et al.  Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. , 2004, European journal of cancer.

[19]  P. Jung,et al.  Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. , 2012, Cancer cell.

[20]  Ash A. Alizadeh,et al.  Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds , 2004, PLoS biology.

[21]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Manuel Hidalgo,et al.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Hiroshi Tanaka,et al.  Clinical Significance of Osteoprotegerin Expression in Human Colorectal Cancer , 2011, Clinical Cancer Research.

[24]  Joel H. Saltz,et al.  Research and applications: Cancer Digital Slide Archive: an informatics resource to support integrated in silico analysis of TCGA pathology data , 2013, J. Am. Medical Informatics Assoc..

[25]  G. Orphanides,et al.  Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines , 2012, BMC Medical Genomics.

[26]  Giovanni Parmigiani,et al.  A Cross-Study Comparison of Gene Expression Studies for the Molecular Classification of Lung Cancer , 2004, Clinical Cancer Research.

[27]  P. Singh,et al.  MUC16-mediated activation of mTOR and c-MYC reprograms pancreatic cancer metabolism , 2015, Oncotarget.

[28]  Jill P. Mesirov,et al.  Subclass Mapping: Identifying Common Subtypes in Independent Disease Data Sets , 2007, PloS one.

[29]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[30]  A. Kimmelman,et al.  Metabolic Dependencies in RAS-Driven Cancers , 2015, Clinical Cancer Research.

[31]  Donald Geman,et al.  A simple and reproducible breast cancer prognostic test , 2013, BMC Genomics.

[32]  Rodrigo Dienstmann,et al.  Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer , 2015, Clinical Cancer Research.

[33]  C. Isella,et al.  Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations , 2011, Clinical Cancer Research.

[34]  Mark Lawler,et al.  Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer , 2016, Clinical Cancer Research.

[35]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[36]  D. Rubin,et al.  Maximum likelihood from incomplete data via the EM - algorithm plus discussions on the paper , 1977 .

[37]  Yujin Hoshida,et al.  Nearest Template Prediction: A Single-Sample-Based Flexible Class Prediction with Confidence Assessment , 2010, PloS one.

[38]  Donald Geman,et al.  switchBox: an R package for k-Top Scoring Pairs classifier development , 2015, Bioinform..

[39]  M. Grégoire,et al.  The role of fibroblasts in tumor behavior , 1995, Cancer and Metastasis Reviews.

[40]  Jaeyun Sung,et al.  Multi-study Integration of Brain Cancer Transcriptomes Reveals Organ-Level Molecular Signatures , 2013, PLoS Comput. Biol..

[41]  Daniel Q. Naiman,et al.  Classifying Gene Expression Profiles from Pairwise mRNA Comparisons , 2004, Statistical applications in genetics and molecular biology.

[42]  Javier Sastre,et al.  Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior , 2012, BMC Cancer.

[43]  R. Powers,et al.  MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer , 2012, Proceedings of the National Academy of Sciences.

[44]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[45]  Jen Jen Yeh,et al.  Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma , 2015, Nature Genetics.

[46]  A. McCullough.  Comprehensive molecular characterization of human colon and rectal cancer , 2013 .

[47]  K. Mimori,et al.  Cell Cycle-Dependent Rho GTPase Activity Dynamically Regulates Cancer Cell Motility and Invasion In Vivo , 2013, PloS one.

[48]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  S. Gabriel,et al.  Pan-cancer patterns of somatic copy-number alteration , 2013, Nature Genetics.

[50]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[51]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[53]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[54]  Philippe Dessen,et al.  Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer , 2012, Clinical Cancer Research.

[55]  Davide Corà,et al.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.

[56]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[57]  S. Krauss,et al.  A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. , 2013, Cancer research.

[58]  Lewis C Cantley,et al.  A colorectal cancer classification system that associates cellular phenotype and responses to therapy , 2013, Nature Medicine.

[59]  Reiko Nishihara,et al.  Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. , 2013, Journal of the National Cancer Institute.

[60]  Pan Du,et al.  lumi: a pipeline for processing Illumina microarray , 2008, Bioinform..

[61]  Xin Wang,et al.  Reconciliation of classification systems defining molecular subtypes of colorectal cancer , 2014, Cell cycle.

[62]  Krzysztof Goryca,et al.  Modeling Oncogenic Signaling in Colon Tumors by Multidirectional Analyses of Microarray Data Directed for Maximization of Analytical Reliability , 2010, PloS one.

[63]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Mira Ayadi,et al.  Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value , 2013, PLoS medicine.

[65]  Elena Baralis,et al.  LAS: A Software Platform to Support Oncological Data Management , 2012, Journal of Medical Systems.

[66]  Giovanni Parmigiani,et al.  MergeMaid: R Tools for Merging and Cross-Study Validation of Gene Expression Data , 2004, Statistical applications in genetics and molecular biology.

[67]  Florian Markowetz,et al.  Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions , 2013, Nature Medicine.

[68]  E. Warren,et al.  Phenotypic and Transcriptional Fidelity of Patient-Derived Colon Cancer Xenografts in Immune-Deficient Mice , 2013, PloS one.